Pneumococcal polysaccharide vaccination in Australia. An examination of barriers and arguments in support of the hospital based approach

Human Vaccines

Volumn 4, Issue 5, 2008, Pages 341-343

  Motbey, Craig ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE   (Australia)

Author keywords

Australia; Barriers; Pneumococcal disease; Pneumococcus; Streptococcus pneumoniae; Vaccination

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DEATH; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HOSPITAL CARE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LOBAR PNEUMONIA; MORBIDITY; MORTALITY; PATIENT ATTITUDE; REVACCINATION; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 54949124943     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.5.6114     Document Type: Review

References (29)

1. Andrews RM, Lester RA. Improving pneumococcal vaccination coverage among older people in Victoria. The Medical Journal of Australia 2000; 173:45-7.
2. Jefferson T, Demicheli V. Polysaccharide pneumococcal vaccines. British Medical Journal (International edition) 2002; 325:292-3.
3. Forrest JM, McIntyre PB, Burgess MA. Pneumococcal disease in Australia. Communicable Diseases Intelligence 2000; 24:89-92.
4. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999; 17:79-84.
5. Fedson DS, Scott JAG. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999; 17:11-8.
6. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12:2177-84.
7. Örtqvist Å, Hedlund J, Kalin M. Streptococcus pneumoniae: Epidemiology, Risk Factors, and Clinical Features. Seminars in Respiratory and Critical Care Medicine 2005; 26:563-74.
8. Krause VL, Reid SJC, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. The Medical Journal of Australia 2000; 173:27-31.
9. Skull SA, Andrews RM, Byrnes GB, Kelly NA, Nolan TM, Brown GV, et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 2007; 25:4631-40.
10. Dear KBG, Andrews RR, Holden J, Tatham DP. Vaccines for preventing pneumococcal infection in adults (Review). The Cochrane Library 2006; 4:1-36.
11. Fedson DS. Pneumococcal Vaccination in the United States and 20 Other Developed Countries, 1981-1996. Clinical Infectious Diseases 1998; 26:1117-23.
12. Plotkin SA, Orenstein WA. Vaccines. Philadelphia, PA: Saunders 2004.
13. Ridda I, MacIntyre CR, Lindley IR, McIntyre PB, Sullivan J, Gilbert GL, Kovoor P, Monolios N, Fox J. Predictors of pneumococcal vaccination uptake in hospitalised patients aged ≥65 years shortly following the commencement of a publicly funded pneumococcal vaccination program in Australia. Human Vaccines 2007; 3:83-6.
14. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004; 23:132-8.
15. Zimmerman RK, Santibanez TA, Fine MJ, Janosky JE, Nowalk MP, Bardella IJ, Raymund M, Wilson SA. Barriers and facilitators of pneumococcal vaccination among the elderly. Vaccine 2003; 21:1510-7.
16. Bovier PA, Chamot E, Gallacchi MB, Loutan L. Importance of patients' perceptions and general practitioners' recommendations in understanding missed opportunities for immunisations in Swiss adults. Vaccine 2001; 19:4760-7.
17. Mieczkowski TA, Wilson SA. Adult pneumococcal vaccination: a review of physician and patient barriers. Vaccine 2002; 20:1383-92.
18. Metersky ML, Mennone JZ, Fine JM. Factors Inhibiting Use of the Pneumococcal Polysaccharide Vaccine: A Survey of Connecticut Physicians. Connecticut Medicine 1998; 62:645-54.
19. Fedson DS. Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly. Clinics in Geriatric Medicine 1992; 8:183-99.
20. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, Lezhava T, Williams WW. Safety of Revaccination With Pneumococcal Polysaccharide Vaccine. JAMA 1999; 281:243-8.
21. Fedson DS. Adult Immunization: Summary of the National Vaccine Advisory Committee Report. JAMA 1994; 272:1133-7.
22. Fedson DS. Influenza and Pneumococcal Immunization Strategies for Physicians. Chest 1987; 91:436-03.
23. Williams WM, Hicksons MA, Kane MA, Kendal AP, Spika JS, Hinman AR. Immunization Policies and Vaccine Coverage Among Adults: The Risk for Missed Opportunities. Annals of Internal Medicine 1988; 108:616-25.
24. Fedson DS. Influenza Prevention and Control: Past Practices and Future Prospects. The American Journal of Medicine 1987; 82:42-7.
25. Fedson DS, Houck P, Bratzler D. Hospital-based influenza and pneumococcal vaccination: Sutton's Law applied to prevention. Infect Control Hosp Epidemiol 2000; 21:692-9.
26. Sokos DR, Skledar SJ, Ervin KA, Nowalk MP, Zimmerman RK, Fox DE, Middleton DB. Designing and implementing a hospital-based vaccine standing orders program. Am J Health Syst Pharm 2007; 64:1096-102.
27. Ridda I, Motbey C, Lam L, Lindley IR. McIntyre PB, Macintyre CR. Factors associated with pneumococcal immunization among hospitalised elderly persons: A survey of patient's perception, attitude and knowledge. Vaccine 2008; 26:234-40.
28. Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Medical Journal of Australia 1999; 170:152-5.
29. Collignon PJ, Turnidge JD. Antibiotic resistance in Streptococcus pneumoniae. The Medical Journal of Australia 2000; 173:58-63.